Clinical Trials · NCT03009981
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Alliance Foundation Trials, LLC.
- Enrollment
- 504
- Start date
- Mar 2017
- Locations
- 69 sites, United States
- Primary endpoint
- PSA progression-free survival in the intent-to-treat population